Precipio logo

PrecipioNASDAQ: PRPO

Profile

Sector:

Healthcare

Country:

United States

IPO:

30 June 2017

Next earnings report:

13 November 2024

Last dividends:

N/A

Next dividends:

N/A
$9.50 M
-83%vs. 3y high
17%vs. sector
-vs. 3y high
-vs. sector
-65%vs. 3y high
36%vs. sector
-91%vs. 3y high
15%vs. sector

Price

regular market | Thu, 31 Oct 2024 13:30:00 GMT
$6.41-$0.07(-1.08%)

Dividend

No data over the past 3 years
$4.44 M-$1.22 M

Analysts recommendations

Institutional Ownership

PRPO Latest News

Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping
globenewswire.com08 October 2024 Sentiment: POSITIVE

The unique assay enables laboratories to provide clinicians with more informed treatment decisions for their patients The unique assay enables laboratories to provide clinicians with more informed treatment decisions for their patients

Precipio Announces Employee Stock Option Plan Repricing
globenewswire.com06 September 2024 Sentiment: POSITIVE

NEW HAVEN, Conn., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  Precipio, Inc.   (NASDAQ: PRPO) announces the Company's repricing of a portion of its employee stock options to ensure their effectiveness as a retention tool for valuable employees.

Precipio, Inc. (PRPO) Q2 2024 Earnings Call Transcript
seekingalpha.com19 August 2024 Sentiment: NEUTRAL

Precipio, Inc. (NASDAQ:PRPO ) Q2 2024 Earnings Conference Call August 19, 2024 5:00 PM ET Company Participants Ilan Danieli - Chief Executive Officer Operator Welcome to the Precipio Second Quarter 2024 Shareholder Update Conference Call. All participants will be in a listen-only mode.

Precipio Announces Q2-2024 Shareholder Update Call
globenewswire.com15 August 2024 Sentiment: POSITIVE

NEW HAVEN, Conn., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  Precipio, Inc.   (NASDAQ: PRPO) , will be hosting its Q2-2024 corporate update call on August 19th at 5:00 PM ET.

Precipio Reports $4.4M for Q2-2024 (unaudited) Revenues, a leap of 30% from Q1-2024
globenewswire.com17 July 2024 Sentiment: POSITIVE

Pathology Revenues in June exceed breakeven target and continue growth trend Pathology Revenues in June exceed breakeven target and continue growth trend

Precipio Inc. Announces Adjournment of Annual Meeting of Stockholders
globenewswire.com13 June 2024 Sentiment: NEGATIVE

New Shareholders Meeting Date: Friday, June 21 at 9 a.m. Eastern Time New Shareholders Meeting Date: Friday, June 21 at 9 a.m. Eastern Time

Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
globenewswire.com12 June 2024 Sentiment: POSITIVE

NEW HAVEN, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company  Precipio, Inc.   (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote their shares immediately today no later than 11pm Eastern Time.

Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
GlobeNewsWire13 February 2024 Sentiment: POSITIVE

NEW HAVEN, Conn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that for the full year of 2023, its unaudited revenues have grown from $9.4M in 2022 to $15.2M in 2023, an increase of 60% year over year.

Precipio, Inc. (PRPO) Q3 2023 Earnings Call Transcript
Seeking Alpha20 November 2023 Sentiment: NEUTRAL

Precipio, Inc. (NASDAQ:PRPO ) Q3 2023 Earnings Conference Call November 20, 2023 5:00 PM ET Company Participants Ilan Danieli - Chief Executive Officer Operator Welcome to the Precipio Third Quarter 2023 Shareholder Update Conference Call. All participants will be in listen-only mode.

Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022
GlobeNewsWire18 October 2023 Sentiment: POSITIVE

NEW HAVEN, Conn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that Q3-2023 (unaudited) revenues have increased 28% to $4.5M from $3.5M in Q2-2023, and have more than doubled from $2.2M from Q3-2022.

What type of business is Precipio?

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.

What sector is Precipio in?

Precipio is in the Healthcare sector

What industry is Precipio in?

Precipio is in the Diagnostics & Research industry

What country is Precipio from?

Precipio is headquartered in United States

When did Precipio go public?

Precipio initial public offering (IPO) was on 30 June 2017

What is Precipio website?

https://www.precipiodx.com

Is Precipio in the S&P 500?

No, Precipio is not included in the S&P 500 index

Is Precipio in the NASDAQ 100?

No, Precipio is not included in the NASDAQ 100 index

Is Precipio in the Dow Jones?

No, Precipio is not included in the Dow Jones index

When was Precipio the previous earnings report?

No data

When does Precipio earnings report?

The next expected earnings date for Precipio is 13 November 2024